Our results suggest that amplification of RSF1 – but not that of the gene encoding for cyclin D1 – may be a candidate predictive biomarker for adjuvant tamoxifen benefit in this high-risk early breast cancer population. The gene discussed is CCND1; the disease is breast carcinoma.